Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

The acute or chronic drug treatments for different neurodegenerative and psychiatric
disorders are challenging from several aspects. The low bioavailability and limited brain …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic
substances and therefore also controls and restricts the entry of therapeutic agents. The …

Diseases of the CNS constitute a significant burden in terms of both personal suffering of the
patients and also in economic terms for the health systems. It has been estimated that the …

Liposomes are safe, biocompatible, and biodegradable spherical nanosized vesicles
produced from cholesterol and phospholipids. Recently, liposomes have been widely …

Nose-to-brain drug delivery has been of great interest for the treatment of many central
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …

Sonodynamic therapy (SDT), as a novel non-invasive strategy for eliminating tumor, has the
advantages of deeper tissue penetration, fewer side effects, and better patient compliance …

The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …